India

BMI View: Cipla's decision to cut the prices of three of its cancer drugs could significantly benefit patients in India and other developing countries, especially in Africa, who previously... 2012-05-08

BMI View: India's growing reputation as a pharmaceutical manufacturing hub is somewhat overhyped. The country exports medicines to developed states and emerging markets but these products... 2012-03-30

BMI View: India's issuance of a compulsory licence for a patented drug is highly significant for several key stakeholders. Patients will now have increased access to a medicine that... 2012-03-15

BMI View: India's pharmaceutical market is highly attractive to drugmakers but it also has several negative characteristics. Combined sales of over-the-counter (OTC) and prescription... 2012-03-05

BMI View: Clinical research organisations (CROs) will increasingly penetrate India's clinical trial sector. Robust economic expansion and relative political stability will support development... 2011-12-02

BMI View: India's pharmaceutical pricing policy is unusually transparent for an emerging market. It also admirably attempts to balance the requirements of the key stakeholders: patients,... 2011-11-11

BMI View: India's healthcare market has strong fundamentals but is constrained by minimal government support, poor oversight, limited foreign investment and a cultural preference for... 2011-11-01

BMI View: India's pharmaceutical market will increasingly attract foreign drugmakers. The government has made a clear statement that it values the contribution of multinationals to... 2011-10-13

BMI View: GlaxoSmithKline (GSK) will acquire and Indian pharmaceutical company or select local medicine brands very shortly, despite the high premiums on these assets. We also believe... 2011-09-28

BMI View: The regulatory environment of India's pharmaceutical market is far below international standards. Rules are poorly designed and implemented improperly. Our key concerns are... 2011-09-19